Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $112.80

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned an average recommendation of “Buy” from the twenty-two research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, nineteen have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $114.45.

A number of research firms have commented on KYMR. Barclays increased their price objective on shares of Kymera Therapeutics from $70.00 to $119.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Jefferies Financial Group increased their price target on shares of Kymera Therapeutics from $73.00 to $122.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Mizuho lifted their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. UBS Group raised Kymera Therapeutics to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Stephens increased their target price on Kymera Therapeutics from $65.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, December 11th.

Insider Transactions at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00. Following the transaction, the chief executive officer directly owned 660,482 shares in the company, valued at approximately $58,895,179.94. This trade represents a 13.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jared Gollob sold 59,576 shares of Kymera Therapeutics stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $61.42, for a total transaction of $3,659,157.92. Following the completion of the transaction, the insider directly owned 109,992 shares of the company’s stock, valued at $6,755,708.64. This trade represents a 35.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 488,585 shares of company stock valued at $41,408,199 over the last quarter. Insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Large investors have recently bought and sold shares of the business. Siren L.L.C. grew its position in Kymera Therapeutics by 9.1% in the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock worth $88,687,000 after purchasing an additional 270,580 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Kymera Therapeutics by 26.3% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock valued at $4,689,000 after buying an additional 22,392 shares during the last quarter. Frontier Capital Management Co. LLC boosted its position in shares of Kymera Therapeutics by 272.7% during the second quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after buying an additional 359,847 shares during the period. Rhumbline Advisers grew its holdings in Kymera Therapeutics by 9.0% in the 1st quarter. Rhumbline Advisers now owns 69,928 shares of the company’s stock worth $1,914,000 after buying an additional 5,771 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Kymera Therapeutics by 77.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after acquiring an additional 10,052 shares during the period.

Kymera Therapeutics Stock Down 1.7%

Shares of KYMR opened at $84.19 on Friday. The business’s 50 day moving average is $65.88 and its two-hundred day moving average is $52.95. Kymera Therapeutics has a 52-week low of $19.44 and a 52-week high of $103.00. The firm has a market cap of $6.06 billion, a price-to-earnings ratio of -23.45 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The company had revenue of $2.76 million for the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. On average, equities analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.